Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ABBOTT LABORATORIES ABT

Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.


NYSE:ABT - Post by User

Comment by north40on Sep 10, 2020 11:18pm
97 Views
Post# 31540701

RE:Why is it not popping

RE:Why is it not popping becauswe there lots else going on with smaller companies...

 COVID-19 TESTING

Kontrol Energy Corp. has provided an update on its Kontrol BioCloud technology.

Lab Testing with Live Virus

Kontrol has received positive lab results for BioCloud testing against the live virus that causes COVID-19. This positive result follows two successful tests against the dormant SARS-CoV-2 virus (see press release dated August 10th, 2020 and press release dated August 27th, 2020).

"We are very pleased that through a methodical approach we have been able to successfully test our technology with the live virus causing COVID-19 and will turn our focus to commercialization of BioCloud," says Paul Ghezzi, CEO of Kontrol. "It has been a long journey to get to this point since the initial concept design in March 2020 and through the great efforts of our team we look forward to delivering a safe space technology solution.""This technology can improve our surveillance of SARS-CoV-2 by monitoring air quality inmultiple settings."Dr. Jimmy D. Dikeakos, Ph.D"This technology will allow for measurement of many different viruses, bacteria, and fungi beyond the immediate need for the virus that causes COVID-19."Dr. David Heinrichs, Ph.D

Commercialization

<< Previous
Bullboard Posts
Next >>